Repare Therapeutics
RPTX
RPTX was delisted on the 27th of January, 2026.
61 hedge funds and large institutions have $828M invested in Repare Therapeutics in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 19 reducing their positions, and 14 closing their positions.
93% more call options, than puts
Call options by funds: $518K | Put options by funds: $268K
1.3% more ownership
Funds ownership: 70.44% → 71.73% (+1.3%)
4% more capital invested
Capital invested by funds: $797M → $828M (+$30.8M)
6% less funds holding
Funds holding: 65 → 61 (-4)
11% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 19
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$36.7M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$21.9M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$14.3M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$13.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$6.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$18.7M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$12.9M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$12.6M |
| 4 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$10.9M |
| 5 |
JP Morgan Chase
New York
|
-$5.98M |
RPTX Hedge Fund Activity: Q2 2021 in Review
61 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q2 2021, worth a combined $828M — up 3.9% from $797M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of RPTX and 10 opened new positions — a net loss of 4 holders — while 19 trimmed existing stakes and 17 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $36.7M. The largest seller was Logos Global Management, cutting an estimated $18.7M.
- 61 institutional investors held Repare Therapeutics (RPTX) as of Q2 2021, down from 65 in Q1 2021.
- Funds reported $828M of Repare Therapeutics stock for Q2 2021, up 3.9% quarter-over-quarter.
- 10 funds opened new Repare Therapeutics positions in Q2 2021 and 14 closed out, a net change of -4 holders.
- The largest Repare Therapeutics buyer in Q2 2021 was T. Rowe Price Associates, an estimated $36.7M added.
- The largest Repare Therapeutics seller in Q2 2021 was Logos Global Management, an estimated $18.7M sold.
Based on aggregated 13F filings for Q2 2021.